Straits Times Index
3,356.44 +17.87 (+0.54%) Nikkei
39,780.58 +149.52 (+0.38%) Hang Seng
17,886.92 +168.31 (+0.95%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,930.63 -363.05 (-0.57%) CMC Crypto 200
1,344.62 +42.54 (+3.27%)
Teva Pharmaceutical Industries Limited (TEVA.TA)
| Previous close | 6,120.00 |
| Open | 6,117.00 |
| Bid | 5,986.00 x 200 |
| Ask | 5,990.00 x 34100 |
| Day's range | 5,849.00 - 6,228.00 |
| 52-week range | 2,786.00 - 6,494.00 |
| Volume | |
| Avg. volume | 1,473,565 |
| Market cap | 68.607B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | 14.86 |
Business WireNew AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
TEL AVIV, Israel, June 28, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use.
Business WireTeva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
TEL AVIV, Israel, June 25, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029.
Business WireTeva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
PARSIPPANY, N.J., June 24, 2024--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
